trial

A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

NCTId NCT02855411
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 35 (actual)
Sponsored by Biogen
Primary completion 2016-09-26
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
35 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2016-08-29
Primary completion
2016-09-26
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
PF-04958242

Sponsors

BiogenLead Sponsor

Sites

16 total
Garden Grove, United StatesGarden Grove, United StatesOceanside, United StatesOrange, United StatesSan Diego, United StatesTorrance, United StatesAtlanta, United StatesHoffman Estates, United StatesHoffman Estates, United StatesLake Charles, United StatesGaithersburg, United StatesBerlin, United States

Linked catalysts

1
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cogn — primary completion2016-09-26

Facts & assertions

4 sourced
Enrollment
35
Phase
PHASE2
Primary Completion Date
2016-09-26
Status
TERMINATED
relationships
The graph out of here
drug
PF-04958242
drug
lead_sponsor
Biogen
company
indication
Cognitive Impairment Associated With Schizophrenia (CIAS)
indication